{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-184488","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2022-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.618816+00:00","generated_at":"2026-06-24T22:19:43.051909+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aileron stops NSCLC trial enrollment after interim data; revises breast cancer trial","bullets":["Interim data from 20 patients: ALRN-6924 patients completed 93% of first 4 chemo cycles vs 78% placebo.","Progression-free survival median 4.6 months on ALRN-6924 vs 3.2 months on placebo.","Composite primary endpoint: 56% cycles free of Grade ≥3 hematologic toxicities vs 50% placebo.","Plans to stop further NSCLC enrollment; apply learnings to breast cancer trial with revised dosing and endpoint.","Will not further enroll 0.3 mg/kg and 0.6 mg/kg cohorts in breast cancer trial; higher dose to be evaluated."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-184488","json":"https://secwatch.observer/filing/0001193125-22-184488.json","markdown":"https://secwatch.observer/filing/0001193125-22-184488.md","text":"https://secwatch.observer/filing/0001193125-22-184488.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312522184488/0001193125-22-184488-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312522184488/d314855d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T22:19:43.051909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}